Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized trial of DNX-2401 added to standard of care for newly diagnosed glioblastoma
2016-001600-40Phase 2Terminated
- Sponsor
- Clínica Universidad de Navarra
- Start
- Jul 2016
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised trial in glioblastoma (GBM) comparing Standard of care + DNX-2401 with Standard of care alone (2 arms). Primary endpoint: Overall Survival. Started Jul 2016; status: terminated.
02
Drugs
Ad5-D24RGD
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2016-001600-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001600-40.